Emeritus Director Jack W. Schuler reported two insider purchases of Biodesix Inc (NASDAQ:BDSX) common stock in late January 2026, totaling $1,180,736 across 100,000 shares.
On January 23, 2026, Schuler acquired 80,000 shares at a weighted average price of $11.8084, for an aggregate cost of $944,672. The execution prices for that block ranged from $11.225 to $12.05. A subsequent purchase on January 26, 2026 consisted of 20,000 shares at a weighted average price of $11.8032, totaling $236,064; those shares were bought at prices between $11.56 and $11.99.
Following these purchases, holdings attributable to the Jack W. Schuler Living Trust stood at 1,563,210 shares. In addition to the trust holdings, Schuler also holds 750,000 shares via the Jack W. Schuler 2025 GRAT.
These insider moves come as Biodesix released preliminary operating results for the fourth quarter and full year of 2025 that notably beat prior guidance and analyst expectations. The company reported a preliminary full-year revenue figure of $88.5 million, which exceeded the high end of its guidance range of $84 million to $88 million and represented a 24% increase compared with the prior year.
Fourth-quarter revenue was preliminarily reported at $28.8 million, a 41% increase year-over-year. In addition to top-line strength, Biodesix reported that it achieved EBITDA profitability in 2025 as part of the preliminary results.
The company's financial trajectory stood in contrast to an earlier quarter in 2025. Biodesix's third-quarter results included a significant miss on earnings per share: the company reported an EPS of -$1.16 versus an expected -$0.06. Despite the EPS shortfall in that quarter, third-quarter revenue of $21.8 million came in above forecasts.
Following those prior results, Canaccord Genuity maintained a Buy rating on Biodesix and kept a $20.00 price target, citing improved test volumes and revenue. The firm attributed part of the revenue improvement to higher average selling prices and more favorable payer dynamics.
The sequence of insider purchases and preliminary financial upside are documented in regulatory filings and the company's announced preliminary results. The reported transaction details - dates, share counts, weighted average prices, and price ranges - are specific to the Schuler purchases and the subsequent reported trust and GRAT holdings.
No additional forward-looking commentary or projections were included in the reported transaction filings or in the preliminary results disclosed by the company.